IFN-alpha2a for Myeloproliferative Disorders

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Myeloproliferative Disorders
IFN-alpha2a - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if Pegasys can help control the disease in patients with essential thrombocythemia, polycythemia vera, myelofibrosis/myeloid metaplasia, and Philadelphia chromosome-negative chronic myelogenous leukemia. The trial will also study the safety of this treatment.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Myeloproliferative Disorders

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 months

3 months
Number of Patients with Complete Response (CR) or Partial Response (PR)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Myeloproliferative Disorders

Trial Design

1 Treatment Group

IFN-alpha2a
1 of 1
Experimental Treatment

84 Total Participants · 1 Treatment Group

Primary Treatment: IFN-alpha2a · No Placebo Group · Phase 2

IFN-alpha2a
Drug
Experimental Group · 1 Intervention: IFN-alpha2a · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,679 Total Patients Enrolled
28 Trials studying Myeloproliferative Disorders
1,467 Patients Enrolled for Myeloproliferative Disorders
Prithviraj Bose, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
11 Total Patients Enrolled
Lucia Masarova, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
156 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are willing and able to comply with the requirements of the protocol for the duration of the study.
You have a performance status of 0, 1, or 2.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.